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The structural variability is often the basis of a wide variety of domain structures with a number of biological activities ascribed to heparin. Thus, in addition to its most widely recognized anticoagulant activity, the heparin molecule has multiple ''non-anticoagulant'' properties that include modulation of various proteases (26, 27) , regulation of cellular proliferation (9, 32) , and anti-inflammatory and immunoregulatory properties (12, 31) , including the modulation of T lymphocytes (21) , inhibition of neutrophil chemotaxis (25) , and eosinophil influx (28) .
Although the precise role of endogenous mast cell heparin is not known, it has recently been demonstrated that commercial heparin possesses significant antiallergic activity (1, 24) . Thus inhaled heparin was shown to attenuate antigen-induced bronchoconstriction in allergic sheep (1) as well as to prevent the bronchoconstrictor response to exercise (4, 15) and antigen in asthmatic subjects (8, 11) . Because many biological actions of heparin are molecular weight dependent (20) , we have hypothesized that lowmolecular-weight heparin fractions may have greater potency and thus may inhibit airway anaphylaxis at much smaller doses. Therefore, we studied the effect of three different low-molecular-weight heparin fractions [medium-molecular-weight heparin (MMWH) KABI 2165; low-molecular-weight heparin (LMWH) CY216; and ultralow-molecular-weight heparin (ULMWH) CY222] on antigen-induced acute bronchoconstrictor response (ABR) and airway hyperresponsiveness (AHR).
MATERIALS AND METHODS

Animal Preparation
Twenty-two adult sheep (mean weight 29 kg, range 26-34 kg) were included in the study. All sheep were allergic to Ascaris suum antigen and had previously been shown to develop ''acute bronchoconstriction'' only after inhalation challenge with the antigen. The study was approved by the Mount Sinai Medical Center's Animal Research Committee.
Measurement of Airway Mechanics
Mean pulmonary airflow resistance was measured in conscious intubated sheep by using the esophageal balloon technique, and thoracic gas volume was measured by body plethysmography by using the techniques previously described (1, 3) . Data were expressed as specific lung resistance (sRL), defined as lung resistance ϫ thoracic gas volume.
Aerosol Delivery System
Aerosols were generated by using a Raindrop disposable nebulizer (Puritan Bennett, Lenexa, KS), which produces an aerosol with a mass median aerodynamic diameter of 3.2 µm (geometric SD 1.9). The output from the nebulizer was directed into a plastic T piece, which was interconnected between the Harvard animal respirator and the endotracheal tube. To control the aerosol delivery, a dosimeter system was used, consisting of a solenoid valve and a source of compressed air (20 pounds/in. 2 ), which was activated for 1 s at the beginning of the inspiratory cycle of the Harvard respirator system. All aerosols were delivered at a tidal volume of 500 ml and a rate of 20 breaths/min.
Agents
Ascaris suum extract (Greer Diagnostics, Lenoir, NC) was diluted with buffered saline to a final concentration of 82,000 protein nitrogen units/ml and delivered as an aerosol over 20 min (400 breaths). The dose of antigen delivered was kept constant for all animals, in all antigen experiments. Carbachol (Sigma Chemical, St. Louis, MO) was dissolved in phosphate-buffered saline for nebulization. MMWH (KABI-2165; mol wt 5,030) was obtained from Pharmacia (Stockholm, Sweden), whereas LMWH (CY216; mol wt 4,270) and ULMWH (CY222; mol wt 2,355) were obtained from Sanofi Pharma (Gentilly, France). The molecular-weight distribution, anti-factor Xa, and APTT activities of heparin fractions are shown in Table 1 .
Experimental Protocol
For every protocol, each animal was studied on 3 different experimental days. On experiment day 1, baseline bronchial reactivity to carbachol was determined, whereas on experiment days 2 and 3 the bronchial reactivity to carbachol was redetermined (at least 2 wk apart) 2 h after the antigen challenge, without or after pretreatment with different doses of fractionated heparins. Group I (n ϭ 7) was pretreated with aerosolized MMWH KABI-2165 (1.25-5 mg/kg); group II (n ϭ 8) was pretreated with aerosolized LMWH CY216 (0.31-5 mg/kg); and group III (n ϭ 7) was pretreated with ULMWH CY222 (0.31-5 mg/kg).
Bronchial reactivity to carbachol. To assess baseline airway responsiveness, cumulative dose-response curves to inhaled carbachol were performed on experiment day 1 by measuring sRL before and immediately after inhalation of buffered saline and after each administration of 10 breaths of increasing concentrations of carbachol [0.25, 0.5, 1.0, 2.0, 3.0, and 4.0% (wt/vol) solution]. The bronchoprovocation was discontinued when sRL increased to 400% above the baseline. The cumulative provocating dose of carbachol (in breath units) that increased sRL to 400% above baseline (PD 4 ) was calculated. One breath unit was defined as 1 breath of a 1% carbachol solution. Baseline dose-response curves to carbachol were performed in all sheep at least 2 wk after their last exposure to antigen.
Effects of low-molecular-weight heparins. The effects of each dose of three different low-molecular-weight heparins were studied on various experiment days. There was at least a 2-wk interval between the treatments. For the control antigen experiments, after baseline measurements of sRL, the sheep were challenged with aerosolized Ascaris suum antigen, and measurements of sRL were repeated within 5 min postchallenge. Two hours postchallenge, when sRL had returned to baseline, a carbachol dose-response curve was ULMWH, ultralow-molecular-weight heparin; LMWH, low-molecular-weight heparin; MMWH, medium-molecular-weight heparin; GAG, glycosaminoglycan. * Chain length Ͻ2,500. To evaluate the effect of MMWH (n ϭ 7) on antigen-induced ABR and AHR, the above protocol was repeated after the sheep were pretreated with various doses of aerosolized KABI-2165 (1.25, 2.5, and 5 mg/kg). Similar protocols were performed to study the effects of LMWH (CY216, n ϭ 8) and ULMWH (CY222, n ϭ 7). The doses of CY216 and CY222 were 0.31, 0.62, 1.25, 2.5, and 5 mg/kg. The fractionated heparins were dissolved in 3 ml of bacteriostatic injection water and administered as an aerosol 30 min before the antigen challenge.
Statistical Analysis
The data are reported as means Ϯ SE and are analyzed by repeated-measures analysis of variance and Newman-Keuls pairwise comparison. Baseline values of PD 4 were compared with postantigen PD 4 (without or with drug pretreatment) by Friedman's two-way analysis of variance followed by nonparametric multiple comparison. Significance was accepted if P Ͻ 0.05 by using a two-tailed test. The power analysis showed that with n ϭ 6 these tests give 80% power to detect sRL changes of Ϯ1.1 cmH 2 O/s. Data were also expressed as percent protection of ABR and AHR %ProtectionofABRϭ ⌬sRL% (control)Ϫ⌬sRL% (drug)
PD 4 (baseline)ϪPD 4 (antigen) ϫ100
RESULTS
Effect of MMWH (KABI-2165, n ϭ 7)
Pretreatment with aerosolized KABI-2165 attenuated the antigen-induced bronchoconstriction (Fig. 1 , Table 2 ). The ABR was inhibited by 24 Ϯ 20% [P ϭ not significant (NS)], 84 Ϯ 9% (P Ͻ 0.05), and 82 Ϯ 7% (P Ͻ 0.05) by inhaled doses of 1.25, 2.5, and 5.0 mg/kg of KABI-2165, respectively. These data were in part published recently (2) .
Inhaled KABI-2165 also attenuated the antigeninduced AHR (Fig. 1, Table 3 ). Postantigen AHR was Table 2 
. Effect of pretreatment with ULMWH (CY222), LMWH (CY216), and MMWH (KABI-2165) on antigen-induced bronchoconstriction
Effect of LMWH (CY216, n ϭ 8)
Pretreatment with aerosolized CY216 attenuated the antigen-induced bronchoconstriction (Fig. 2, Table 2 ). The ABR was inhibited by Ϫ16 Ϯ 14% (P ϭ NS), 25 Ϯ 15% (P ϭ NS), 50 Ϯ 20% (P Ͻ 0.05), 60 Ϯ 11% (P Ͻ 0.05), and 79 Ϯ 6% (P Ͻ 0.05) by 0.31, 0.62, 1.25, 2.5, and 5.0 mg/kg doses of CY216, respectively.
Inhaled CY216 also attenuated the antigen-induced AHR (Fig. 2, Table 3 ). Postantigen AHR was inhibited by 32 Ϯ 17% (P ϭ NS), 30 Ϯ 11% (P ϭ NS), 48 Ϯ 12% (P Ͻ 0.05), 49 Ϯ 12% (P Ͻ 0.05), and 108 Ϯ 15% (P Ͻ 0.05) by 0.31, 0.62, 1.25, 2.5, and 5.0 mg/kg doses of CY216, respectively.
Effect of ULMWH (CY222, n ϭ 7)
Pretreatment with CY222 attenuated the antigeninduced bronchoconstriction (Fig. 3, Table 2 ). The ABR was inhibited by 11 Ϯ 21% (P ϭ NS), 75 Ϯ 8% (P Ͻ 0.05), 78 Ϯ 8% (P Ͻ 0.05), 79 Ϯ 9% (P Ͻ 0.05), and 79 Ϯ 3% (P Ͻ 0.05) by 0.31, 0.62, 1.25, 2.5, and 5.0 mg/kg doses of CY222, respectively.
Inhaled CY222 also attenuated the antigen-induced AHR (Fig. 3, Table 3 ). Postantigen AHR was inhibited by 18 Ϯ 21% (P ϭ NS), 68 Ϯ 18% (P Ͻ 0.05), 107 Ϯ 26% (P Ͻ 0.05), 131 Ϯ 35% (P Ͻ 0.05), and 102 Ϯ 8% (P Ͻ 0.05) by 0.31, 0.62, 1.25, 2.5, and 5.0 mg/kg doses of CY222, respectively.
Molecular-Weight Dependence
Based on the above data, the minimum effective doses and inhibitory dose causing 50% protection (ID 50 ) of the different-molecular-weight fractions of heparin against ABR and AHR were determined. The minimum effective doses of MMWH, LMWH, and ULMWH against ABR were 2.5, 1.25, and 0.62 mg/kg, respectively, whereas the minimum effective doses against AHR were 5, 1.25, and 0.62 mg/kg, respectively ( Figs. 1-3 ; Tables 2 and 3) . ULMWH (CY222) was the most potent agent, with ID 50 of 0.5 mg/kg, against both ABR and AHR. LMWH (CY216) showed intermediate efficacy, with ID 50 values of 1.25 and 2.5 mg/kg against ABR and AHR, respectively. In contrast, MMWH (KABI-2165) was the least (Fig. 4) . Thus, for LMWH and MMWH, the ID 50 values were lower against ABR than against AHR, whereas for ULMWH the ID 50 against the two end points was the same. Overall, there was an inverse relationship between the protection of ABR and AHR and the molecular weight of fractions.
DISCUSSION
The results of this study demonstrate that 1) fractionated low-molecular-weight heparins attenuate antigeninduced acute bronchoconstriction and AHR; 2) there is an inverse relationship between the molecular weight and the antiallergic activity of fractionated heparins; and 3) ULMWH is the most effective antiallergic fraction.
Inhaled unfractionated heparin has been shown to attenuate antigen-induced acute bronchoconstriction and postantigen AHR in allergic sheep (1, 3, 5, 6) . This study further extends those observations by demonstrating that fractionated low-molecular-weight heparins, including MMWH, LMWH, and ULMWH, caused a significant inhibition of ABR and AHR. The antiallergic activity of fractionated heparins was molecular weight dependent, and an inverse relationship between the molecular weight of each fraction and its relative potency was observed. ULMWH was the most potent fraction, with ID 50 against ABR of 0.5 mg/kg, whereas LMWH and MMWH fractions had ID 50 of 1.25 and 1.8 mg/kg, respectively. The inhibition of postantigen AHR by each fraction was also inversely related to molecular weight and showed even greater dose dependency than the inhibition of ABR. Thus, in terms of inhibiting ABR, ULMWH was 2.5-fold and 3.5-fold more potent than LMWH and MMWH fractions, respectively, whereas it showed 5-fold and 9-fold greater potency than LMWH and MMWH in attenuating AHR.
The present study also demonstrates molecularweight-dependent differences between the antiallergic activity of various fractionated low-molecular-weight heparins. Whereas the minimal effective doses of ULMWH inhibiting ABR and AHR were comparable, higher doses of LMWH and MMWH were required for attenuation of AHR than ABR. Thus ID 50 values of ULMWH for AHR vs. ABR demonstrated a ratio of one, whereas the ID 50 values of LMWH and MMWH for AHR were ϳ2-and 2.5-fold greater than for ABR. The reason for these differences among various low-molecular-weight heparins is not clear. In addition to the differences in molecular weight, variations in the antiallergic properties of various fractions may be linked to the saccharide chain length and/or variations in the chemical structure. Low-molecular-weight heparins are a diverse group of drugs and show considerable differences in terms of anti-Xa, anti-IIa, APTT activity, and percent glycosaminoglycan content (13, 30) . In particular, ULMWH (CY222) has the highest percent glycosaminoglycan content, the lowest molecular weight, and the highest percentage of chain length Ͻ2,500. It is possible that antiallergic activity may reside in the ultralow-molecular-weight chains (i.e., Ͻ2,500) of ULMWH.
The potential differences of in vivo pharmacokinetics of various inhaled low-molecular-weight heparin fractions may partly account for quantitative differences in their antiallergic activities. Although high doses of inhaled low-molecular-weight heparin (Ͼ270 mg) show prolonged anticoagulant activity (17) , the bioavailability and elimination half-life for antiallergic activity of aerosolized low-molecular-weight heparins are not known. Pharmacokinetic studies with aerosolized unfractionated heparin have demonstrated significant antiasthmatic activity lasting up to 6-12 h in sheep and 3-6 h in human subjects with asthma (5, 15) . It is possible that inhaled ULMWH fractions may have better tissue penetration and bioavailability at potential sites of action, thus attenuating both ABR and AHR at very low doses. Alternatively, the potential sites and mechanisms of action of ULMWH may be different. It has been proposed that the antiallergic activity of unfractionated heparin may be mediated by inhibition of inositol 1,4,5-triphosphate-mediated mast cell me-diator release (3, 6, 16, 18) . Low-molecular-weight heparins have also been shown to inhibit inositol 1,4,5-triphosphate-induced Ca 2ϩ release (29) and to attenuate anti-immunoglobulin E-induced mast cell degranulation (2) . Whether the potent antiallergic activity of ULMWH observed in the present study is mediated by inhibition of mast cell-mediator release is not known at present. It is possible that inhaled unfractionated heparin, MMWH, and LMWH by acting only on mast cells may possess antiallergic activity (2, 4, 24) , whereas ULMWH may also possess mast-cell-independent antiinflammatory properties, thus inhibiting AHR at very low doses.
The antiallergic activity of inhaled unfractionated heparin observed in previous studies was related to its non-anticoagulant properties, as plasma thromboplastin time was not prolonged (1, 4, 15) . This has been confirmed in a recent study demonstrating that a non-anticoagulant fraction of heparin also attenuated the antigen-induced acute bronchoconstriction in allergic sheep (2) . Although in the present study anti-Xa activity was not measured, it has been shown that only very high doses of low-molecular-weight heparin (Ͼ270 mg) increase anti-Xa activity (17) , thus strongly suggesting that antiallergic activity of fractionated lowmolecular-weight heparins is related to non-anticoagulant properties (1, 2, 4, 15) .
It has been suggested that aerosol heparin may have beneficial effects in alleviating asthma symptoms, although no definite bronchodilatory activity was observed (14) . The results of this study clearly demonstrate that the antiallergic activity of heparin resides in the ultralow-molecular-weight chains. Allergic airway inflammation is closely related to AHR and plays a major role in the pathophysiology of asthma (7) . Modification of allergic airway responses and AHR by ULMW heparins not only would provide further insight into the pathophysiology of asthma but may also be of clinical importance.
